Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Here's Why RBC Capital Raised Price Target On Cigna

  • Cigna Corp (NYSE:CI) posted 1Q22 adjusted EPS well above expectations on enterprise-wide growth, with a particularly solid performance in specialty pharmacy and better than expected MCR on lower testing and treatment costs. 
  • The company raised FY22 guidance on 1Q outperformance.
  • The analysts raised the price target to $272 from $235, with a Sector Perform rating. 
  • The analysts write that Evernorth saw sustained momentum across its specialty pharmacy business lines as Accredo and CuraScript continued to support outsized growth in the specialty platform. 
  • Management notes strong demand for Evernorth’s services among existing and new clients early in the 2023 selling season. 
  • With management continuing to view medicare advantage (MA) as a sustainable long-term growth opportunity, RBC looks forward to specific strategies for rejuvenating the MA book at CI’s Investor Day in June. 
  • Government membership decline was offset on the commercial side by solid growth in ASO membership.
  • Management expects the international life divestiture to close later in 2Q than initially anticipated, which pushes the timing of buybacks to later in the year. 
  • Price Action: CI shares are down 1.70% at $262.36 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.